Long-acting beta-adrenoceptor agonist

Chronic Obstructive Pulmonary Disease Forecast and Market Analysis to 2026: Triple Therapies will Drive Modest Growth of the COPD Market - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 6, 2021
Pharmaceutical, Health, Cardiology, Respiratory diseases, Health, Respiratory therapy, Chronic lower respiratory diseases, Muscarinic antagonists, Asthma, Chronic obstructive pulmonary disease, Long-acting beta-adrenoceptor agonist, Shortness of breath, Inhaler, Lung, COPD: Journal of Chronic Obstructive Pulmonary Disease, Respiratory diseases, Health, Respiratory therapy, Chronic lower respiratory diseases, Muscarinic antagonists, Asthma, Chronic obstructive pulmonary disease, Long-acting beta-adrenoceptor agonist, Shortness of breath, Inhaler, Lung, COPD: Journal of Chronic Obstructive Pulmonary Disease

The "Chronic Obstructive Pulmonary Disease Forecast and Market Analysis to 2026" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chronic Obstructive Pulmonary Disease Forecast and Market Analysis to 2026" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Chronic obstructive pulmonary disease (COPD) is defined by persistent airflow limitation (reduction in the ability to exhale at a normal rate and volume).
  • While chronic and progressive dyspnea (shortness of breath) is a key symptom, patients may also present with productive cough.
  • Triple inhaled corticosteroid/long-acting beta 2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) fixed-dose combination therapies delivered through a single inhaler bring convenience to more severe patients.

Innoviva Announces Strategic Repurchase of GSK’s Equity Stake

Retrieved on: 
Thursday, May 20, 2021
Managed care, Pharmaceutical, Health, Medical devices, Drugs, Ellipta, Long-acting beta-adrenoceptor agonist, Beta2-adrenergic agonist, XC2, Fluticasone furoate/vilanterol

We believe that it materially accelerates the delivery of our strategy, while also meaningfully improving our shares\xe2\x80\x99 long-term trading dynamics with an aligned shareholder base.

Key Points: 
  • We believe that it materially accelerates the delivery of our strategy, while also meaningfully improving our shares\xe2\x80\x99 long-term trading dynamics with an aligned shareholder base.
  • Under the Long-Acting Beta2 Agonist (\xe2\x80\x9cLABA\xe2\x80\x9d) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR\xc2\xae/BREO\xc2\xae ELLIPTA\xc2\xae and ANORO\xc2\xae ELLIPTA\xc2\xae.
  • The words \xe2\x80\x9canticipate\xe2\x80\x9d, \xe2\x80\x9cexpect\xe2\x80\x9d, \xe2\x80\x9cgoal\xe2\x80\x9d, \xe2\x80\x9cintend\xe2\x80\x9d, \xe2\x80\x9cobjective\xe2\x80\x9d, \xe2\x80\x9copportunity\xe2\x80\x9d, \xe2\x80\x9cplan\xe2\x80\x9d, \xe2\x80\x9cpotential\xe2\x80\x9d, \xe2\x80\x9ctarget\xe2\x80\x9d and similar expressions are intended to identify such forward-looking statements.
  • No forward-looking statements can be guaranteed and actual results may differ materially from such statements.

Chiesi Group receives European Marketing Authorization for Trimbow® inhalation powder (beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium) delivered through NEXThaler, an extrafine formulation fixed triple combination therapy fo

Retrieved on: 
Wednesday, April 21, 2021
Pulmonology, Respiratory therapy, Health, XC2, Formoterol, Bronchodilator, Long-acting beta-adrenoceptor agonist, Chronic obstructive pulmonary disease, Inhaler

\xe2\x80\x9cChiesi triple therapy is today the first and only triple fixed combination treatment providing both pMDI and DPI devices as options for patients and physicians.

Key Points: 
  • \xe2\x80\x9cChiesi triple therapy is today the first and only triple fixed combination treatment providing both pMDI and DPI devices as options for patients and physicians.
  • The Group is committed to becoming carbon neutral by the end of 2035.\nChiesi\xe2\x80\x99s triple therapy is an extrafine formulation, fixed triple combination, of beclometasone dipropionate (ICS) / formoterol fumarate (LABA) / glycopyrronium (LAMA).
  • Lancet 2016;\xc2\xa0388:\xc2\xa0963\xe2\x80\x93973.\nVestbo\xc2\xa0J,\xc2\xa0Papi\xc2\xa0A,\xc2\xa0Corradi\xc2\xa0M,\xc2\xa0et al.\xc2\xa0Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
  • Lancet 2017;\xc2\xa0389:\xc2\xa01919\xe2\x80\x931929.\nPapi\xc2\xa0A,\xc2\xa0Vestbo\xc2\xa0J,\xc2\xa0Fabbri\xc2\xa0L,\xc2\xa0et al.\xc2\xa0Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.

Chiesi Group receives the European Marketing authorization for the extrafine triple-combination therapy for the treatment of moderate to severe asthma

Retrieved on: 
Monday, February 1, 2021
Respiratory therapy, Health care, Health sciences, Medicine, Dosage forms, Asthma, Inhaler, Long-acting beta-adrenoceptor agonist, Chiesi Farmaceutici, Combination drugs

It is the first extrafine fixed triple combination therapy in a single inhaler to be approved for use in asthma patients.

Key Points: 
  • It is the first extrafine fixed triple combination therapy in a single inhaler to be approved for use in asthma patients.
  • PARMA, Italy, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Chiesi, an international research-focused Healthcare group (Chiesi Group), announces that the European Commission has granted the marketing authorization for Chiesi extrafine triple therapy combination ICS/LABA/LAMA in a single inhaler, for the treatment of asthma.
  • Chiesi is committed to developing and delivering alternatives to aid patients in the management of their respiratory conditions and treatment.
  • The prevalence of asthma in the European Union (EU) is 8.2% in adults and 9.4% in children.

Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020

Retrieved on: 
Tuesday, October 13, 2020
Drugs, Clinical medicine, Health, Chronic lower respiratory diseases, Combination drugs, Muscarinic antagonists, Chronic obstructive pulmonary disease, Long-acting beta-adrenoceptor agonist, RPL-554, Phosphodiesterase, Fluticasone furoate/umeclidinium bromide/vilanterol, Fluticasone furoate/vilanterol

U.S. sales of medicines used for chronic maintenance therapy of COPD were $9.6 billion in 2019.

Key Points: 
  • U.S. sales of medicines used for chronic maintenance therapy of COPD were $9.6 billion in 2019.
  • About 1.2 million U.S. COPD patients on dual/triple inhaled therapy, long-acting beta-agonist (LABA)/long-acting muscarinic antagonist (LAMA) +/- inhaled corticosteroid (ICS) remain uncontrolled, experiencing symptoms that impair quality of life.
  • Ensifentrine (RPL554) is an investigational, first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4).
  • The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) for COPD maintenance treatment.

Sosei Heptares Notes That Enerzair® Breezhaler® (QVM149) has been Recommended for Approval in the European Union for Treating Uncontrolled Asthma

Retrieved on: 
Friday, May 1, 2020
Asthma, Respiratory therapy, Quaternary ammonium compounds, Long-acting beta-adrenoceptor agonist, Muscarine, Medical specialties, Medicine, Health

If the EC follows this recommendation and approves Enerzair Breezhaler, it will become the first LABA/long-acting muscarinic antagonist (LAMA)/ICS fixed-dose combination for uncontrolled asthma patients.

Key Points: 
  • If the EC follows this recommendation and approves Enerzair Breezhaler, it will become the first LABA/long-acting muscarinic antagonist (LAMA)/ICS fixed-dose combination for uncontrolled asthma patients.
  • Under the agreement, Sosei Heptares is entitled to certain development and sales-based milestones, and royalties on net sales upon successful commercialisation of Enerzair Breezhaler.
  • Shinichi Tamura, President and CEO of Sosei Heptares, commented:"The recommendation for the approval of Enerzair Breezhaler is a great step towards it becoming available to the many uncontrolled asthma patients in the European Union.
  • Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey.

Sosei Heptares Notes That Enerzair® Breezhaler® (QVM149) has been Recommended for Approval in the European Union for Treating Uncontrolled Asthma

Retrieved on: 
Friday, May 1, 2020
Asthma, Respiratory therapy, Quaternary ammonium compounds, Long-acting beta-adrenoceptor agonist, Muscarine, Medical specialties, Medicine, Health

If the EC follows this recommendation and approves Enerzair Breezhaler, it will become the first LABA/long-acting muscarinic antagonist (LAMA)/ICS fixed-dose combination for uncontrolled asthma patients.

Key Points: 
  • If the EC follows this recommendation and approves Enerzair Breezhaler, it will become the first LABA/long-acting muscarinic antagonist (LAMA)/ICS fixed-dose combination for uncontrolled asthma patients.
  • Under the agreement, Sosei Heptares is entitled to certain development and sales-based milestones, and royalties on net sales upon successful commercialisation of Enerzair Breezhaler.
  • Shinichi Tamura, President and CEO of Sosei Heptares, commented:"The recommendation for the approval of Enerzair Breezhaler is a great step towards it becoming available to the many uncontrolled asthma patients in the European Union.
  • Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey.

GSK Submits Filing to FDA for Trelegy Ellipta Use in Patients With Asthma

Retrieved on: 
Wednesday, October 2, 2019
FDA, Health, Clinical trials, General Health, Pharmaceutical, Drugs, Medicine, Combination drugs, Clinical medicine, Ellipta, Chronic lower respiratory diseases, Long-acting beta-adrenoceptor agonist, Fluticasone furoate/vilanterol, Muscarinic antagonists, Umeclidinium bromide/vilanterol, Respiratory therapy, Chronic obstructive pulmonary disease, asthma, the CAPTAIN Study, Trelegy Ellipta (FF/UMEC/VI) in the US, GSK, Innoviva

Trelegy Ellipta was approved in the US in September 2017 for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD).

Key Points: 
  • Trelegy Ellipta was approved in the US in September 2017 for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD).
  • Christopher Corsico, SVP Development, GSK said: Around 30% of asthma patients adherent to ICS/LABA combination therapy still experience symptoms.
  • If approved, this filing would make Trelegy Ellipta the first and only single inhaled triple therapy available for both asthma and COPD in the US.
  • Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA, ANORO ELLIPTA and TRELEGY ELLIPTA, which were jointly developed by Innoviva and GSK.

New data reinforces benefits of Spiolto® Respimat® in improving patient outcomes

Retrieved on: 
Tuesday, October 1, 2019
Biotechnology, Medical devices, Health, Pharmaceutical, Chemical compounds, Medicine, Clinical medicine, Respimat, Olodaterol, Tiotropium bromide, Boehringer Ingelheim, Chronic obstructive pulmonary disease, Long-acting beta-adrenoceptor agonist, Boehringer, European Respiratory Society, Ingelheim am Rhein

Boehringer Ingelheim announced Spiolto (tiotropium/olodaterol) Respimat data being presented at the European Respiratory Society (ERS) 2019 Congress.

Key Points: 
  • Boehringer Ingelheim announced Spiolto (tiotropium/olodaterol) Respimat data being presented at the European Respiratory Society (ERS) 2019 Congress.
  • A novel bidimensional, pooled analysis enabled us to directly compare six LAMA/LABA fixed-dose combinations and demonstrate that tiotropium/olodaterol improved patient outcomes more than the other treatments in the class.
  • Varying efficacy and safety of combinations in the same class should be considered for a patient-centred approach in COPD.
  • Boehringer Ingelheim will present data from 11 abstracts relating to the COPD portfolio, host two scientific symposia and post daily podcasts featuring leading respiratory experts throughout the ERS Congress.

Chronic Obstructive Pulmonary Disease Market 2019-2026: AstraZeneca's Triple Therapy PT010 will Strengthen its Franchise

Retrieved on: 
Tuesday, June 18, 2019
Drugs, Chronic obstructive pulmonary disease, Combination drugs, Long-acting beta-adrenoceptor agonist, Pulmonary disease, chronic obstructive, severe early-onset

DUBLIN, June 18, 2019 /PRNewswire/ -- The "Chronic Obstructive Pulmonary Disease Forecast and Market Analysis to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 18, 2019 /PRNewswire/ -- The "Chronic Obstructive Pulmonary Disease Forecast and Market Analysis to 2026" report has been added to ResearchAndMarkets.com's offering.
  • Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide.
  • AstraZeneca's triple therapy PT010 will strengthen its franchise, allowing it to offer a comprehensive treatment option.
  • Payers are likely to demand favorable pricing for new combination LABA/LAMAs and triple combination ICS/LABA/LAMA inhalers.